Which category of respiratory drugs does ensifentrine-Ohtuvayre belong to?

Ensifentine Inhalation Suspension Solution (Ensifentrine), trade nameOhtuvayre, is a new dual-action inhaled drug, mainly used for the maintenance treatment of adults with chronic obstructive pulmonary disease (COPD). COPD is a common chronic respiratory disease characterized by gradual narrowing of the airways, causing patients to experience symptoms such as chronic cough, shortness of breath, and difficulty breathing. As an innovative drug, exefantine has a unique dual mechanism of action and improves the symptoms of COPD patients by inhibiting two major biological pathways.

Ensefentin belongs to a new class of respiratory drugs that is a combination of anticholinergic andβ2-adrenoceptor agonists. Its unique feature is that it can help patients maintain better airway patency by simultaneously inhibiting the effects of cholinergic receptors and β2-adrenergic receptors in the respiratory tract, thereby reducing the occurrence of COPD symptoms. Cholinergic receptor antagonism can relieve bronchoconstriction, while β2-adrenergic receptor agonism can promote bronchiectasis. This dual mechanism effectively improves dyspnea and wheezing problems in COPD patients.

As an inhaled drug, exefentine acts locally and directly on the respiratory tract, avoiding the occurrence of systemic side effects. Compared with traditional treatment methods, exefantine can provide longer-lasting effects and have fewer side effects, which can improve patients' lung function, reduce symptoms, and improve patients' quality of life. For COPD patients who require long-term maintenance treatment, exefantine undoubtedly provides a safer and more effective treatment option.

Due to its dual mechanism, the application of exefantine is not limited to relieving the acute symptoms of COPD More importantly, it plays a key role in long-term maintenance treatment, helping to delay the progression of the disease and reduce the frequency of acute exacerbations, providing a new treatment option for COPD patients.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html